← Eichor
Study identifier: NCT06840886 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of PHST001 in Advanced Solid Tumors

Condition: Advanced Solid Tumors · Ovarian Cancer · Endometrial Cancer  ·  Sponsor: Pheast Therapeutics

PhasePhase 1
Planned participants272
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 monotherapy and in combination with chemotherapy as well as assess the anti-tumor activity of PHST001 and chemotherapy in Phase 1b.

This description comes directly from the study's public registry record.

Talk to the study team

Andrew Ferguson/VP Clinical Development, PhD  ·  434-249-2349  ·  medical@pheast.com

Always discuss trial participation with your own doctor first.

Locations (20)

Precision NextGen Oncology & Research CenterBeverly Hills, California, United StatesRecruiting
USC Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting
Stanford University School of MedicinePalo Alto, California, United StatesRecruiting
Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health OneDenver, Colorado, United StatesRecruiting
Yale Cancer CenterNew Haven, Connecticut, United StatesRecruiting
University of Chicago Medical CenterChicago, Illinois, United StatesRecruiting
Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
University of Michigan Rogel Cancer CenterAnn Arbor, Michigan, United StatesRecruiting
START Center for Cancer Research - MidwestGrand Rapids, Michigan, United StatesRecruiting
START Center for Cancer Research - Long Island New YorkLake Success, New York, United StatesRecruiting
Mount SinaiNew York, New York, United StatesRecruiting
Duke Cancer InstituteDurham, North Carolina, United StatesRecruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06840886